Asthma/COPD Flashcards
Salmeterol (Serevent)
Class: Bronchodilator - long-acting β2 agonist
Mech: Relax bronchial smooth muscle, inhibit mediator release (mast cells, basophils), increase mucociliary clearance, suppression of microvascular permeability (BMMM)
Thera: used for long-term control of asthma symptoms (always in comination with inhaled steroids)
Important SE’s: Musculoskeletal tremor, Tachycardia, hyperglycemia, hypokalemia, hypomagnesemia
Other SE’s: Tolerance with chronic use, Prolonged QTc, lactic acidosis, paradoxical bronchospasm
Misc: 10-15 minutes to take action, 6-12 hours (max) of duration; nebulizer delivers more, but greater side effects; oral is least effective (requires more dose –> side effects); can be used night symptoms, but not ideal
Asthma is
- chronic inflamm of airways
- recurrent episodes of wheezing, SOB, chest tightness (SEC)
- Variable airway obstruction, often completely reversible
COPD is a
- persistent airway limitation
- progressive (not fully reversible)
- enhanced chronic inflamm responses (cough, SOB, increased sputum)
Some key similarities and differences b/w COPD and asthma:
Sim: both inflamm; Diff: 1. TH2 dom in astham, TH1 in COPD 2. IgE producing in asthma 3. reversible in asthma, fixed in COPD 4. Bronchial hyperreactivity in asthma 5. Smoking risk factor for COPD; genetics, environment in asthma
Some epidemiology:
- Females > males for percent asthma
- Females more likely to get asthma as we get older, and more AA pop mortality
- Men with greater death rate by COPD than females, but more females die of it
- Could be underdiagnosing COPD and hence undertreating
In asthma and the ____ model, what helps mediate early inflamm? Late inflamm?
allergen;
leads to IgE coating mast cells and degranulation, and also T lymphocyte activity (both with IL4, IL5; mast cells with leukotriens, prostaglandin D, platelet activating factor);
late: eosinophils and neutrophils with their mediators (e.g. MBP for eosinophils) and this leads to more bronchospasm
Rather than think of the allergen model of asthma, what is a viable model to think of?
Bronchial hyper-reactivity model (cold air or maybe exercise)
What three things does COPD help cause? Why?
- fibrosis (small airways)
- Alveolar wall destruction (emphysema)
- Mucus hypersecretion (hypertrophy of mucous glands0;
Imbalance of proteases and antiproteases
FAM
Important mech of action of bronchodilators (beta 2 agonist)?
increases cAMP through G-protein receptor interaction and activation of AC;
Albuterol, terbutaline, metoproterenol, pirbutol:
Class: Bronchodilator - short-acting β2 agonist)
Mech: Relax bronchial smooth muscle, inhibit mediator release (mast cells, basophils), increase mucociliary clearance, suppression of microvascular permeability
Thera: Prevent or reduce exercise-induced bronhospasms; mild asthma & acute exacerbations
Important SE’s: Musculoskeletal tremor, Tachycardia, hyperglycemia, hypokalemia, hypomagnesemia; Tolerance with chronic use (downregulate beta 2 receptors), Prolonged QTc, lactic acidosis, paradoxical bronchospasm
Misc: 5 minutes to take action, 4-6 hours duration; nebulizer delivers more, but greater side effects. Note: Levalbuterol is R-isomer of albuterol.
Levalbuterol:
- R isomer of albuterol
- Just beta agonist effects
- No inflamm or SE’s like tachy due to no S isomer
- No significant difference in clinical or pharmacological outcome
Salmeterol, formoterol, indacaterol:
S: partial agonist; F: full agonist; I: ultra long acting (only in COPD);
Onset: 10-30 min; duration: 12 hrs or more;
Highly lipid soluble and binds to secondary exosite;
USED IN COMBO WITH INHALED CS IN ASTHMA!!!!!
Comparison of tiotropium and ipratropium bromide:
- Half life of tio is longer at M3 receptor (can dose 1x/day);
- Tio will dissociate faster from M2 receptor and keep its M3 activity longer
Ipratropium (Atrovent); Tiotropium; Atropine
Class: Quarternary amine antimuscarinic
Mech: Blocks vagal pathways and decreases vagal tone to bronchial smooth muscle; also blocks the reflex bronchoconstriction caused by inhaled irritants
Thera: First-line agent for chronic COPD; status asthmaticus (w/ nebulized β2-agonists); no role in chronic stable asthma
SE’s: Typical antimuscarinic effects; acute angle glaucoma; paradoxical bronchospasm GAP (inhibition of vagal induced bronchoconstriction would require high dose than current therapeutic doses); consider receptor selectivity;
Misc: Note: tiotropium has anti-inflammatory properties and decreases mucus secretion.
Aclidinium bromide:
Class: Quarternary amine antimuscarinic
Mech: Blocks vagal pathways and decreases vagal tone to bronchial smooth muscle; also blocks the reflex bronchoconstriction caused by inhaled irritants
Thera: Functionally similar to tiotropium
1. structurally and functionally similar to tio
2. M3>M2 affinity
3. Half life at M3: 29 hours
4. Short circulation half life: 2.4 min (Less systemic & CNS side effects than other antimuscarinics due to extremely short circulation half-life)
5. Higher dose can be given safely;
same SE’s as antimuscarainics